Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Liquidia Corporation LQDA

Healthcare  —  Drug Manufacturers Specialty & Generic
68.43 (2.52) (3.55%) as of 25 Sep
Market cap
$6.4B
P/E
43.6×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Liquidia Technologies, Inc. (LQDA) Business Profile

Updated before January 2025

Company Overview

Liquidia Technologies, Inc. (NASDAQ: LQDA) is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for the treatment of pulmonary and other diseases. Founded in 2004 and headquartered in Morrisville, North Carolina, Liquidia leverages its proprietary PRINT® (Particle Replication In Non-Wetting Templates) technology to design and manufacture precise drug particles. This technology enables the company to develop therapies with enhanced efficacy, safety, and patient outcomes.

The company is led by a team of experienced professionals in the pharmaceutical and biotechnology industries. As of 2023, Roger Jeffs serves as the Chief Executive Officer, bringing decades of leadership experience in drug development and commercialization. The leadership team also includes other key executives such as Tushar Shah, M.D., Chief Medical Officer, and Michael Kaseta, Chief Financial Officer, who collectively drive Liquidia’s strategic vision and operational excellence.

Core Business Segments

Liquidia operates primarily in the biopharmaceutical sector, with a focus on developing therapies for pulmonary arterial hypertension (PAH) and other related conditions. The company’s core business segments include:

1. Pulmonary Arterial Hypertension (PAH) Therapies

Liquidia’s flagship product is YUTREPIA™ (treprostinil), an inhalation powder designed to treat PAH. YUTREPIA leverages the PRINT® technology to deliver precise and consistent doses of treprostinil, improving patient compliance and outcomes. The product is currently under regulatory review and is expected to be a game-changer in the PAH treatment landscape.

2. Drug Delivery Technology

The company’s proprietary PRINT® technology is a cornerstone of its business. This platform allows Liquidia to design drug particles with uniform size, shape, and composition, enabling targeted drug delivery and improved therapeutic performance. While primarily used for internal product development, the technology also has potential applications in partnerships and licensing agreements with other pharmaceutical companies.

3. Research and Development (R&D)

Liquidia invests heavily in R&D to expand its pipeline of innovative therapies. The company is exploring additional applications of its PRINT® technology in other therapeutic areas, including oncology and infectious diseases.

Business Model

Liquidia’s business model revolves around the integration of advanced drug delivery technology with innovative therapeutic development. The company generates revenue through:

  • Product Sales: Once approved, YUTREPIA and other pipeline products will serve as primary revenue drivers.
  • Licensing Agreements: Liquidia licenses its PRINT® technology to other pharmaceutical companies, creating an additional revenue stream.
  • Collaborations and Partnerships: The company collaborates with industry leaders to co-develop therapies and expand the applications of its technology.

This diversified approach allows Liquidia to mitigate risks associated with product development while maximizing its market potential.

Strategic Direction

Liquidia is committed to advancing its mission of improving patient outcomes through innovative therapies. Key strategic priorities include:

  • Regulatory Approvals: Securing FDA approval for YUTREPIA and other pipeline products remains a top priority.
  • Pipeline Expansion: The company is actively exploring new therapeutic areas where its PRINT® technology can be applied.
  • Sustainability Goals: Liquidia aims to minimize its environmental footprint by adopting sustainable manufacturing practices and reducing waste.
  • Global Market Expansion: The company plans to expand its presence in international markets, particularly in regions with high unmet medical needs.

Competitive Landscape

Liquidia operates in a highly competitive biopharmaceutical market. Key competitors include:

  • United Therapeutics Corporation: A leader in PAH therapies, offering products such as Tyvaso® and Remodulin®.
  • Johnson & Johnson (via Actelion Pharmaceuticals): A major player in the PAH market with products like Opsumit® and Uptravi®.
  • Other Emerging Biotech Firms: Companies developing novel drug delivery technologies and PAH treatments also pose competition.

Liquidia differentiates itself through its PRINT® technology, which offers unique advantages in drug design and delivery.

Risk Factors

Like any biopharmaceutical company, Liquidia faces several risks, including:

  • Regulatory Risks: Delays or rejections in regulatory approvals could impact the company’s growth prospects.
  • Market Dependence: The company’s reliance on YUTREPIA as a primary revenue driver poses a concentration risk.
  • Supply Chain Disruptions: Challenges in sourcing raw materials or manufacturing components could affect product availability.
  • Competitive Pressure: Intense competition in the PAH market may limit market share and pricing power.

Recent Developments

In recent years, Liquidia has made significant strides in advancing its pipeline and corporate strategy:

  • YUTREPIA Regulatory Progress: The company has submitted a New Drug Application (NDA) for YUTREPIA, with regulatory decisions expected soon.
  • Partnerships: Liquidia has entered into strategic collaborations to expand the applications of its PRINT® technology.
  • Corporate Milestones: The company has strengthened its leadership team and secured additional funding to support its growth initiatives.

Global developments, such as the COVID-19 pandemic, have underscored the importance of innovative drug delivery technologies, further validating Liquidia’s strategic focus.

Investment Considerations

Investors considering Liquidia should weigh the following factors:

Strengths

  • Innovative Technology: The PRINT® platform offers a competitive edge in drug design and delivery.
  • Strong Pipeline: YUTREPIA and other pipeline products have significant market potential.
  • Experienced Leadership: The management team has a proven track record in the biopharmaceutical industry.

Risks

  • Regulatory Uncertainty: Delays in product approvals could impact revenue generation.
  • Market Competition: Established players in the PAH market pose significant challenges.
  • Financial Risks: As a pre-commercial company, Liquidia relies on external funding to sustain operations.

Conclusion

Liquidia Technologies, Inc. is well-positioned to become a leader in the biopharmaceutical industry, thanks to its innovative PRINT® technology and promising pipeline of therapies. While the company faces challenges such as regulatory hurdles and market competition, its strategic focus on innovation and patient outcomes provides a strong foundation for future growth. Investors should closely monitor Liquidia’s progress, particularly with regard to YUTREPIA’s regulatory approval and commercialization.